Traduction de «Maladie engendrant maladies » (Français → Anglais) :

disabling illness [ crippling disease | crippling condition | incapacitating disease ]

infectious disease [ bacterial disease | cholera | communicable disease | contagious disease | leprosy | malaria | parasitic disease | sleeping sickness | trypanosomiasis | tuberculosis | viral disease | viral diseases | yellow fever ]

blue disease | blue ear disease | blue-ear disease of pigs | mysterious pig disease | mysterious swine disease | mystery pig disease | new pig disease | porcine epidemical abortion | porcine reproductive and respiratory syndrome | purple ears disease | MSD [Abbr.] | PRRS [Abbr.]

axophthalmic goitre | basedowified goiter | Basedow's disease | exophthalmic goiter | exophthalmica | Flajani's disease | Graves disease | hyperthyreosis | hyperthyroidism | Parry's disease | thyroid cachexia | thyroiditis | thyrotoxia | thyrotoxicosis | toxic goiter

disease of the nervous system [ Alzheimer's disease | CJD | Creutzfeldt-Jakob disease | degenerative disease of the nervous system | multiple sclerosis | neurological disease | neuropathy | transmissible spongiform encephalopathy | TSE ]

disease prevention [ prevention of disease | prevention of illness | preventive medicine | prophylaxis | screening for disease | screening for illness | preventive medicine(UNBIS) ]

illness benefit [ sickness benefit | sick pay | sickness allowance | sickness indemnity | health benefit | sick benefit | sick pay allowance ]

trinucleotide repeat disorder | triplet repeat disorder | trinucleotide repeat disease | triplet repeat expansion disorder | trinucleotide-repeat expansion disease | disorder caused by expansion of triplet repeats

sexually transmitted infection [ STI | sexually transmitted disease | venereal disease ]

However, for clinial trials carried out in high morbidity or high mortality disease, where efficacy end-points could also be SUSARs or when mortality or another ’serious’ outcome, that may potentially be reported as a SUSAR, is the efficacy end-point in a clinical trial, the integrity of the clinical trial may be compromised if the blind is systematically broken.

However, for clinial trials carried out in high morbidity or high mortality disease, where efficacy end-points could also be SUSARs or when mortality or another ’serious’ outcome, that may potentially be reported as a SUSAR, is the efficacy end-point in a clinical trial, the integrity of the clinical trial may be compromised if the blind is systematically broken.

Recognises the need to maintain and use genetic resources for long-term food security and to broaden the genetic base of modern plant and animal breeding programmes; recognises that organic farms face a shortage of new varieties that are resistant to pests and diseases and which could be cultivated without the use of plant protection products; supports the concept of access and benefit sharing, but urges implementation of the Nagoya Protocol, under Regulation (EU) No 511/2014, and Implementing Regulation (EU) 2015/1866, so that breeders are not deterred by the complexity and cost arising from using wild material to introduce new traits ...[+++] such as pest and disease resistance, nutritional quality and environmental resilience; notes that this should be done without disempowering rural communities that have stewarded species and bred varieties throughout the years.

The purpose of entitlement to sick leave is different, since it enables a worker to recover from an illness that has caused him to be unfit for work.